Table 1.
Characteristics of included studies
| Trials | Year | Duration (y) | Treatments | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatments 1 | Age (y) | New cases of diabetes/total | Treatments 2 | Age (y) | New cases of diabetes/total | Treatments 3 | Age (y) | New cases of diabetes/total | |||
| ALLHAT22 | 2002 | 4.0 | ACEIs | 67.0 | 119/4096 | CCBs | 67.0 | 154/3954 | Diuretics | 67.0 | 302/6766 |
| EWPHE24 | 1991 | 4.7 | Diuretics | >60 | 29/416 | Placebo | >60 | 20/424 | |||
| MRC‐E18 | 1992 | 5.8 | β blockers | 70.2 | 37/1102 | Diuretics | 70.2 | 43/1081 | Placebo | 70.2 | 34/2213 |
| SCOPE17 | 2003 | 3.7 | ARBs | 76.0 | 93/2167 | Placebo | 76.0 | 115/2175 | |||
| SHEP16 | 1998 | 3.0 | Diuretics | 76.0 | 140/1631 | Placebo | 76.0 | 118/1578 | |||
| STOP‐215 | 1999 | 4.0 | ACEIs | 70.0‐84.0 | 93/1970 | β blockers | 70.0‐84.0 | 97/1960 | CCBs | 70.0‐84.0 | 95/1965 |
| ADaPT13 | 2012 | 4.0 | ACEIs | 69.0 | 151/896 | Diuretics | 69.0 | 76/423 | |||
| EMPHASIS‐HF11 | 2012 | 1.8 | ARBs | 69.0 | 33/894 | Placebo | 69.0 | 36/952 | |||
| COPE12 | 2012 | 3.0 | ARBs | >60 | 7/498 | β blockers | >60 | 18/534 | Diuretics | >60 | 15/501 |
| VALUE14 | 2004 | 4.2 | ARBs | 67.0 | 690/5087 | CCBs | 67.0 | 840/5074 | |||
| ANBP‐223 | 2015 | 4.1 | ACEIs | 65.0‐84.0 | 138/2000 | Diuretics | 65.0‐84.0 | 200/2826 | |||
| INVEST19 | 2003 | 2.7 | CCBs | >60 | 665/8098 | Placebo | >60 | 569/8078 | |||
| HOPE21 | 2001 | 4.5 | ACEIs | >60 | 102/2837 | Placebo | >60 | 155/2883 | |||
| INSIGHT20 | 2000 | 3.0 | CCBs | 60.0‐70.0 | 96/2508 | Diuretics | 60.0‐70.0 | 137/2511 | |||
Abbreviations: ACEIs: angiotensin‐converting enzyme inhibitors; ADaPT: ACE inhibitor‐based vs diuretic‐based antihypertensive primary treatment in patients with pre‐diabetes; ALLHAT: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial; ANBP‐2: Second Australian National Blood Pressure trial; ARBs: angiotensin II receptor blockers; CCBs: calcium channel blockers; COPE: The Combination Therapy of Hypertension to Prevent Cardiovascular Events; EMPHASIS‐HF: The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EWPHE: The European Working Party on High Blood Pressure in the Elderly; HOPE: Heart Outcomes Prevention Evaluation; INVEST: International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment; MRC‐E: Medical Research Council in the Elderly; SCOPE: The Study on Cognition and Prognosis in the Elderly; STOP‐2: The Swedish Trial in Old Patients with Hypertension‐2 study; VALUE: The Valsartan Antihypertensive Long‐term Use Evaluation.